Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Cash from Operations (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Cash from Operations for 8 consecutive years, with 15270000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Operations fell 158.29% to 15270000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 73276000.0, a 52.07% decrease, with the full-year FY2024 number at 58445000.0, up 30.52% from a year prior.
  • Cash from Operations was 15270000.0 for Q3 2025 at Precision Biosciences, up from 20271000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 68072000.0 in Q1 2021 to a low of 31464000.0 in Q1 2023.
  • A 5-year average of 13355684.21 and a median of 20271000.0 in 2025 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: soared 362.72% in 2021, then plummeted 179.12% in 2023.
  • Precision Biosciences' Cash from Operations stood at 23681000.0 in 2021, then rose by 7.76% to 21843000.0 in 2022, then soared by 61.44% to 8423000.0 in 2023, then crashed by 121.81% to 18683000.0 in 2024, then rose by 18.27% to 15270000.0 in 2025.
  • Per Business Quant, the three most recent readings for DTIL's Cash from Operations are 15270000.0 (Q3 2025), 20271000.0 (Q2 2025), and 19052000.0 (Q1 2025).